In the past decade, the management of differentiated thyroid cancer (DTC) underwent a
paradigm shift toward the use of risk stratification with the goal of maximizing the benefit and …

Purpose The aim of this study was to determine clinical outcomes in patients with
differentiated thyroid cancer after surgery and activity-adjusted 131 I therapy informed by …

The concept of individualized therapy is rapidly gaining recognition in the management of
patients with differentiated thyroid cancer (DTC). This Review provides an overview of the …

The majority of patients with differentiated thyroid cancer are cured with standard primary
treatments including surgery, radioactive iodine and TSH suppression. A small proportion of …

OBJECTIVE. The paradigm of theranostics is based on tailoring therapy for the purpose of
optimizing outcomes. This principle is being applied to radioactive iodine therapy …

Differentiated thyroid cancer is the most frequent type of thyroid cancer with an increasing
incidence in the last decades. The initial management is represented by surgical treatment …

Radioiodine is important in the diagnostic and therapeutic armamentarium of differentiated
thyroid cancer (DTC); however, many controversies persist. This article addresses some of …

Until recently, the usual treatment for differentiated thyroid cancers (DTC) with a size> 1.0 cm
undisputedly consisted of total or near-total thyroidectomy followed by radioiodine …

I-131 is an established diagnostic and therapeutic modality for patients with functioning
residual disease after surgery, and is widely used for remnant ablation and treating …

This review of radioactive iodide treatment (RAIT) extends from historical origins to its
modern utilization in differentiated thyroid cancer (DTC). The principles embedded in the …